文献速递骨软组织肉瘤与黑色素瘤

帕博利珠单抗单药治疗晚期黑色素瘤的长期安全性及其与临床结局的关系:一项里程碑分析

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
PubMed 文献 · Eur J Cancer · 2020-12-24

该分析基于KEYNOTE-001、002和006三项试验,纳入1567例接受至少1剂帕博利珠单抗的晚期黑色素瘤患者,中位随访42.4个月。结果显示大多数不良事件为轻中度,3/4级治疗相关不良事件发生率为17.7%,发生2例帕博利珠单抗相关死亡。里程碑分析(第147天无进展患者)显示,是否发生免疫介导不良事件或使用全身性皮质激素,客观缓解率相似,但使用皮质激素者中位无进展生存期数值上较短。

要点

  • 长期随访未发现新的安全性信号,3/4级治疗相关不良事件发生率17.7%。
  • 任何级别免疫介导不良事件发生率23.0%,3/4级为6.9%,多发生于治疗16周内。
  • 里程碑分析中,发生免疫介导不良事件者与未发生者的客观缓解率相似(64.6% vs 63.0%)。

核心结论

  • 长期随访未发现帕博利珠单抗在晚期黑色素瘤中的新毒性信号。
  • 里程碑分析显示,无论是否发生免疫介导不良事件或使用全身性皮质激素,帕博利珠单抗疗效相似。

研究设计与样本

  • 对KEYNOTE-001、KEYNOTE-002和KEYNOTE-006三项试验中接受至少1剂帕博利珠单抗的患者进行分析。
  • 共纳入1567例患者,中位随访42.4个月。
  • 通过里程碑分析(第147天无进展患者)解决领先时间偏倚。

主要发现

  • 大多数不良事件为轻中度,3/4级治疗相关不良事件发生于17.7%的患者,发生2例帕博利珠单抗相关死亡。
  • 任何级别免疫介导不良事件发生于23.0%的患者,最常见为甲状腺功能减退(9.1%)、肺炎(3.3%)和甲状腺功能亢进(3.0%);3/4级免疫介导不良事件发生于6.9%的患者。
  • 大多数免疫介导不良事件发生于治疗16周内。
  • 里程碑分析中,发生免疫介导不良事件者(n=79)与未发生者(n=384)的客观缓解率分别为64.6%和63.0%,中位至缓解时间均为5.6个月,中位缓解持续时间分别为20.0个月和25.3个月,中位无进展生存期分别为17.0个月和17.7个月,中位总生存期分别为未达到和43个月(p=0.1104)。
  • 里程碑分析中,接受全身性皮质激素者(n=17)与未接受者(n=62)的客观缓解率分别为70.6%和62.9%,中位至缓解时间分别为6.4个月和5.6个月,中位无进展生存期分别为9.9个月和17.0个月,中位缓解持续时间分别为14.2个月和未达到,中位总生存期均为未达到。

临床怎么用

  • 长期随访数据支持帕博利珠单抗在晚期黑色素瘤中的安全性。
  • 免疫介导不良事件的发生或全身性皮质激素的使用可能不显著影响帕博利珠单抗的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Long-term safety of pembrolizumab in melanoma was analyzed in KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006. PATIENTS AND METHODS: Analysis involved patients who received ≥1 pembrolizumab dose. Lead-time bias was addressed via landmark analyses in patients who were progression-free before day 147. RESULTS: Adverse events (AEs) were analyzed for 1567 patients (median follow-up, 42.4 months). Most AEs were mild/moderate; grade 3/4 treatment-related AEs occurred in 17.7% of patients. Two pembrolizumab-related deaths occurred. Any-grade immune-mediated AEs (imAEs) occurred in 23.0%, most commonly hypothyroidism (9.1%), pneumonitis (3.3%), and hyperthyroidism (3.0%); grade 3/4 imAEs occurred in 6.9% of patients. Most imAEs occurred within 16 weeks of treatment. In landmark analysis, patients who did (n = 79) versus did not (n = 384) develop imAEs had similar objective response rates (ORRs) (64.6% versus 63.0%); median time to response (TTR), 5.6 months for both; median duration of response (DOR), 20.0 versus 25.3 months; median progression-free survival (PFS), 17.0 versus 17.7 months; median overall survival (OS), not reached (NR) versus 43 months (p = 0.1104). Patients who did (n = 17) versus did not (n = 62) receive systemic corticosteroids had similar ORRs (70.6% vs. 62.9%) and median TTR (6.4 vs. 5.6 months) but numerically shorter median PFS (9.9 vs. 17.0 months); median DOR, 14.2 months versus NR; median OS, NR for both. CONCLUSIONS: These results enhance the knowledge base for pembrolizumab in advanced melanoma, with no new toxicity signals after lengthy follow-up of a large population. In landmark analyses, pembrolizumab efficacy was similar regardless of imAEs or systemic corticosteroid use. CLINICAL TRIAL REGISTRY: NCT01295827, NCT01704287, NCT01866319.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Robert C, Hwu WJ, Hamid O, et al. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Eur J Cancer. 2020. PMID: 33360855. doi:10.1016/j.ejca.2020.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。